Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
TG Therapeutics, Inc. TGTX
$31.09
-$2.42 (-7.77%)
На 18:00, 12 мая 2023
-45.32%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
4983850560.00000000
-
week52high
35.67
-
week52low
3.48
-
Revenue
2785000
-
P/E TTM
-23
-
Beta
2.06089900
-
EPS
-1.49000000
-
Last Dividend
0.00000000
-
Next Earnings Date
01 мая 2023 г. в 12:30
Описание компании
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| B. Riley Securities | Buy | Buy | 13 июн 2022 г. |
| B of A Securities | Underperform | 20 мая 2022 г. | |
| Goldman Sachs | Sell | Sell | 19 апр 2022 г. |
| B. Riley Securities | Buy | Buy | 19 апр 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 18 апр 2022 г. |
| Goldman Sachs | Sell | Sell | 30 дек 2022 г. |
| Evercore ISI Group | Outperform | Outperform | 30 дек 2022 г. |
| B. Riley Securities | Buy | Buy | 30 дек 2022 г. |
| B of A Securities | Underperform | Underperform | 29 дек 2022 г. |
| Evercore ISI Group | Outperform | Outperform | 24 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Echelard Yann | A | 201848 | 9000 | 06 янв 2023 г. |
| Charney Laurence N | D | 234729 | 30000 | 04 янв 2023 г. |
| Power Sean A | A | 200000 | 200000 | 20 июл 2022 г. |
| Power Sean A | A | 643483 | 75000 | 20 июл 2022 г. |
| WEISS MICHAEL S | A | 1900000 | 1900000 | 20 июл 2022 г. |
| Charney Laurence N | A | 264729 | 43732 | 20 июл 2022 г. |
| Echelard Yann | A | 192848 | 43732 | 20 июл 2022 г. |
| Hoberman Kenneth | A | 222685 | 43732 | 20 июл 2022 г. |
| HUME DANIEL | A | 198239 | 43732 | 20 июл 2022 г. |
| Lonial Sagar | A | 128732 | 43732 | 20 июл 2022 г. |
Новостная лента
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today
The Motley Fool
01 мая 2023 г. в 16:28
Biotech stocks were fairly volatile today, thanks to another buyout and a spate of earnings reports. Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics were among the most volatile in the space.
TG Therapeutics, Inc. (TGTX) Q1 2023 Earnings Call Transcript
Seeking Alpha
01 мая 2023 г. в 13:15
TG Therapeutics, Inc. (NASDAQ:TGTX ) Q1 2023 Earnings Conference Call May 1, 2023 8:30 AM ET Company Participants Mike Weiss - Chairman & CEO Adam Waldman - CCO Sean Power - CFO Jenna Bosco - IR Conference Call Participants Eric Joseph - JPMorgan Ed White - H. C. Wainwright Prakhar Agrawal - Cantor Fitzgerald Matt Kaplan - Ladenburg Thalmann Mayank Mamtani - B.
Top 1% Biotech TG Therapeutics Obliterates Bullish Sales Calls — And Rockets
Investors Business Daily
01 мая 2023 г. в 12:30
TG Therapeutics more than doubled Wall Street's first-quarter sales expectations on Monday, and TGTX stock rocketed to a five-month high. The post Top 1% Biotech TG Therapeutics Obliterates Bullish Sales Calls — And Rockets appeared first on Investor's Business Daily.
TG Therapeutics (TGTX) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
01 мая 2023 г. в 09:55
TG Therapeutics (TGTX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.51 per share a year ago.
TG Therapeutics to Host Conference Call on First Quarter 2023 Financial Results and Business Update
GlobeNewsWire
28 апр 2023 г. в 16:30
NEW YORK, April 28, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Monday, May 1, 2023, at 8:30 ET to discuss results for the first quarter 2023 and provide a business outlook for remainder of the year. Michael S.